Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Selling, General & Admin	12.63
Research & Development	56.14
Operating Expenses	68.76
Operating Income	-68.76
Interest Expense	-3.41
Interest & Investment Income	0.7
Pretax Income	-71.47
Net Income	-71.47
Net Income to Common	-71.47
Shares Outstanding (Basic)	5
Shares Outstanding (Diluted)	5
EPS (Basic)	-13.45
EPS (Diluted)	-13.45
EBIT	-68.76

Updated Jun 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q